As relates to the recently published Editorial of the Colombian Journal of Anesthesiology (Revista Colombiana de Anestesiología) entitled "Has the time come to restrict the clinical use of dipyrone?,"1 we agree with the author regarding the regulatory steps that must be adopted on the use not only of di...
In their editorial, Gómez-Duarte1 suggests that the association of dipyrone with multiple adverse effects should lead to reconsider its use. We are of the opinion that such position neglects part of the available evidence, although we recognize that based on such evidence different views arise with rega...
Upon carefully reading Gómez-Duarte's1 editorial on the need to restrict the use of dipyrone due to its adverse and potentially lethal effects, we thought that some of the expressed ideas must be reviewed in detail in the light of current controversies and methodological limitations of the available evi...
Dipyrone (or metamizole) is an analgesic and antipyretic for oral or parenteral administration. Its action mechanism is directly related to the inhibition of the signaling of TRPA1 (Transient Receptor Potential Ankirin 1). The TRPA1 ion channel, located in the plasma membrane of a subpopulation of nocice...
Abstract Introduction: Dipyrone has been positioned in several countries as one of the first over-the-counter options for pain management. Its possible adverse effects are known worldwide; among them, agranulocytosis is the most lethal, with a mortality of approximately 10% and an associated risk of 1 p...
